The effect of deferasirox on endocrine complications in children with thalassemia

Pediatric Hematology and Oncology
Burçak Kurucu BilginNese Yarali

Abstract

Endocrine system dysfunctions are the significant complications of excessive iron overload in beta thalassemia patients. The aim of this study was to evaluate the long-term effect of chelation with deferasirox on endocrine complications. The study group consisted of children with beta thalassemia who had been evaluated for the growth and pubertal development, bone metabolism, thyroid/parathyroid functions, glucose metabolism dysfunctions in the department of pediatric hematology of Ankara Dışkapı Child Health and Diseases Hematology Oncology Training And Research Hospital between 2009-2011 and reevaluated after deferasirox chelation therapy in 2018. Thirty-one transfusion dependent beta-thalassemia patients were enrolled for the study. Seventeen (54.8%) patients were male and the mean age was 16.9 ± 3.8 (9-23) years. Splenectomy was performed in 11 patients (35.5%). In the initial evaluation, 26 patients (84%) received deferoxamine and/or deferiprone and five (17%) patients received deferasirox as a chelator; in the final evaluation all patients were receiving deferasirox. The mean duration of deferasirox treatment was 5.9 ± 2.02 years (1-10 years). Of the 26 patients who had endocrine complications between 2009-2011, 18 were r...Continue Reading

References

Sep 30, 2003·Journal of Pediatric Endocrinology & Metabolism : JPEM·Sakineh MohammadianAb Sadeghi-Nejad
Feb 28, 2004·Blood·Melody J CunninghamUNKNOWN Thalassemia Clinical Research Network
May 30, 2006·Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry·Damla GoksenTimur Kose
Nov 30, 2006·Acta Paediatrica·Olcay NeyziFirdevs Bas
Jul 17, 2009·British Journal of Haematology·Maria G VogiatziUNKNOWN Thalassemia Clinical Research Network
May 25, 2010·Orphanet Journal of Rare Diseases·Renzo Galanello, Raffaella Origa
May 24, 2014·Pediatric Hematology and Oncology·Pamir IsikBahattin Tunc
Jul 23, 2015·Journal of Pediatric Hematology/oncology·Venée N TubmanUNKNOWN Thalassemia Clinical Research Network

❮ Previous
Next ❯

Citations

Feb 7, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Ning LiQing Geng
Jul 11, 2021·Clinical and Experimental Medicine·Cihangir SevimliZeynep Karakas
Aug 2, 2021·Italian Journal of Pediatrics·Ramadan A MahmoudMarwa S Farhan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.